This section and the included press releases are presented for historical purposes only. Press releases and other documents speak only as of the date thereof.
-- Phase 2b Trial Results Demonstrated SNA-120 Had Significant Impact on Psoriasis and Was Well-Tolerated WESTLAKE VILLAGE, Calif. , June 10, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that the results of its
WESTLAKE VILLAGE, Calif. , Feb. 19, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that it has commenced a proposed underwritten public offering of its common stock. All shares of common stock to be sold in the
-- Biopsy data support strong clinical effect observed in Phase 2 trials with SNA-120 -- Following Positive End-of-Phase 2 meeting with FDA , Sienna continues toward enrolling first patient in Phase 3 program in second half of 2019 WESTLAKE VILLAGE, Calif.
WESTLAKE VILLAGE, Calif. , Aug. 05, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that the Company has retained Cowen as an independent financial advisor to assist in exploring financial and strategic alternatives
WESTLAKE VILLAGE, Calif. , Oct. 07, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that the Company has filed a Premarket Notification 510(k) submission to the U.S. Food and Drug Administration ( FDA ) for
WESTLAKE VILLAGE, Calif. , Sept. 17, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that it has elected to file a voluntary petition to allow restructuring under Chapter 11 of the Bankruptcy Code.
WESTLAKE VILLAGE, Calif. , Feb. 20, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $2.50 per share.
-- John W. Smither Departing for Personal Reasons WESTLAKE VILLAGE, Calif. , March 21, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced the promotion of Alexander Azoy to Chief Financial Officer (CFO). Mr.
-- Company Completed Positive End-of-Phase 2 Meeting with FDA for SNA-120 in Psoriasis WESTLAKE VILLAGE, Calif. , May 08, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA) today reported the Company’s financial results for the first quarter of 2019.
WESTLAKE VILLAGE, Calif. , March 14, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today reported the Company’s financial results for the fourth quarter and full year of 2018. “We are pleased to report the results of our 2018
WESTLAKE VILLAGE, Calif. , May 09, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA) today announced that Frederick C. Beddingfield III , M.D., Ph.D., President and Chief Executive Officer of Sienna, is scheduled to present at the Bank of America Merrill Lynch Health Care
WESTLAKE VILLAGE, Calif. , June 20, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that Frederick C. Beddingfield III , M.D., Ph.D., President and Chief Executive Officer of Sienna, is scheduled to present at the
WESTLAKE VILLAGE, Calif. , March 05, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that Frederick C. Beddingfield III , M.D., Ph.D., President and Chief Executive Officer of Sienna, is scheduled to present at the
WESTLAKE VILLAGE, Calif. , May 21, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that Paul F. Lizzul , M.D., Ph.D., Chief Medical Officer, and Silvio Traversa , B.Sc., Ph.D., Chief Scientific Officer, are
WESTLAKE VILLAGE, Calif. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that Frederick C. Beddingfield III , M.D., Ph.D., President and Chief Executive Officer of Sienna®, is scheduled to present at the 6 th Annual Dermatology Summit, Sunday, Jan.
-- SNA-001 addresses a large unmet need in laser hair removal by treating light hair using a topical solution of silver photoparticles, an ultra-efficient light absorber -- -- If cleared, SNA-001 has potential to expand the $3 billion U.S. laser hair removal market as an effective option for